rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    RCEL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      AVITA Medical Shares Rose 329% In A Year, Medicare Resets Its Billing Codes Next
      Nov 14Seeking AlphaRCEL
      Avita Medical reports warrant exercises by Perceptive and OrbiMed investors By Investing.com
      Nov 13Investing.comRCEL
      TD Cowen raises Avita Medical stock price target on growth outlook
      Nov 12Investing.comRCEL
      The Bet Behind AVITA Medical's 393% Run

      If you had backed AVITA Medical at the very start of 2026, the result would look dramatic on any brokerage screen. Holding AVITA Medical from the start of the year would have returned 393.4%, including dividends. That kind of move invites a hard look at what early shareholders were really judging. If the Medicare reimbursement dispute, trauma expansion push and cost cuts were all still unresolved on 2026-01-01, which of those uncertainties would you have leaned into and which would you have...

      Nov 10Yahoo FinanceRCEL
      AVITA Medical to Host Investor Webinar Briefing
      Nov 8Yahoo FinanceRCEL
      AVITA Medical (RCEL) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 6The Globe and MailRCEL
      Avita Medical Q3 Earnings Call Highlights
      Nov 6Yahoo FinanceRCEL
      AVITA Medical Inc (AVHHL) (Q3 2026) Earnings Call Highlights: Revenue Surges 53% as AVITA ...

      AVITA Medical Inc (AVHHL) posted $26.1 million in Q3 revenue with 84% gross margins, lifted its 2026 outlook to $92-$94 million, and expects to reach cash flow breakeven in Q4.

      Nov 6Yahoo FinanceRCEL
      Avita Medical earnings beat by $0.04, revenue topped estimates
      Nov 5Investing.comRCEL
      AVITA Medical Q3 2026 Earnings Call Transcript
      Nov 5BenzingaRCEL
      AVITA Medical Reports Third Quarter Results
      Nov 5Yahoo FinanceRCEL
      AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
      Nov 5Yahoo FinanceRCEL
      TD Cowen raises Avita Medical stock price target on growth outlook
      Nov 3Investing.comRCEL
      What AVITA Medical Holders Bought Into Before A 347% Run
      Oct 26Yahoo FinanceRCEL
      AVITA Medical to Announce Third Quarter 2026 Financial Results

      VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 6, 2026, at 8:30 a.m.

      Oct 20Yahoo FinanceRCEL
      AVITA Medical Q2 2026 Earnings Call Transcript - AVITA Medical (NASDAQ:RCEL)

      On Thursday, AVITA Medical (NASDAQ:RCEL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts

      Oct 12BenzingaRCEL
      AVITA Medical (RCEL) Stock Sees Fair Value Lift After PermeaDerm Data And Q2 Beat

      AVITA Medical’s updated valuation work now points to a fair value of $12.29, compared with the prior $11.06, which gives you a fresh reference point for where analysts see the stock’s central value today. The shift lines up with commentary that has turned more constructive after the PermeaDerm I data, recent quarterly results, and a view that current evidence and reimbursement trends support a higher fair valuation range. Read on to see what is driving this evolving narrative and how to track...

      Oct 1Yahoo FinanceRCEL
      AVITA Medical at Morgan Stanley conference: growth returns, costs held down
      Sep 16Investing.comRCELMS
      AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference

      VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial

      Sep 2Yahoo FinanceRCEL
      All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy

      Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

      Aug 31Yahoo FinanceRCEL
      AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases

      AVITA Medical is back in focus after fair value estimates in recent models shifted from US$9.00 to US$11.06, marking a sizeable uplift in the central price target. Analysts link these updated targets to new PermeaDerm-I data, RECELL usage trends, reimbursement developments and changes to the Stedical agreements, as they reassess how AVITA Medical might scale its burn care portfolio. As you read on, you will see how these moving targets fit into the broader narrative and what to watch to stay...

      Aug 25Yahoo FinanceTESTRCEL
      AVITA Medical: Favorable Reimbursements For Skin Wound Care (NASDAQ:RCEL)

      RCEL outlook: more predictable RECELL reimbursement, RECELL GO rollout, PermeaDerm economics, and Q4 2026 breakeven target.

      Aug 24Seeking AlphaRCEL

      This is the newest page. Registered accounts read further back.